TY - JOUR
T1 - Pityriasis Rubra Pilaris after Moderna COVID-19 Vaccination
T2 - A Case Report and Literature Review
AU - Liu, Yi A.
AU - Dai, Julia
AU - Nagarajan, Priyadharsini
AU - Torres-Cabala, Carlos A.
AU - Aung, Phyu P.
AU - Prieto, Victor G.
AU - Cho, Woo Cheal
N1 - Publisher Copyright:
Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.
PY - 2023/3/1
Y1 - 2023/3/1
N2 - To date, over 60% of the world’s population has received at least 1 dose of coronavirus disease 2019 (COVID-19) vaccination, with over 12 billion doses administered globally. Commonly reported adverse effects of COVID-19 vaccination include fever, headache, myalgia, and injection site reactions. The spectrum of documented cutaneous reactions after COVID-19 vaccination is broad; however, pityriasis rubra pilaris (PRP) or PRP-like eruption secondary to COVID-19 vaccine is exceedingly rare, with only 17 cases previously reported to date in the English literature. In this article, we describe an additional case of COVID-19 vaccination-associated PRP in a 50-year-old woman with a history of metastatic breast carcinoma, who developed a widespread cutaneous eruption characteristic of PRP, including palmoplantar keratoderma, 10 days after her third dose of Moderna COVID-19 vaccine. Punch biopsy specimen showed epidermal hyperplasia with overlying hyperkeratosis, alternating orthokeratosis and parakeratosis and focal follicular plugging, supporting the diagnosis of PRP. The patient improved within weeks of initiating oral acitretin and topical steroids, with resolution achieved after 3 months of continued therapy. To the best of our knowledge, this is the third reported case of Moderna COVID-19 vaccination-associated PRP and collectively the 18th after the administration of all COVID-19 vaccines currently available, including Pfizer–BioNTech, and AstraZeneca.
AB - To date, over 60% of the world’s population has received at least 1 dose of coronavirus disease 2019 (COVID-19) vaccination, with over 12 billion doses administered globally. Commonly reported adverse effects of COVID-19 vaccination include fever, headache, myalgia, and injection site reactions. The spectrum of documented cutaneous reactions after COVID-19 vaccination is broad; however, pityriasis rubra pilaris (PRP) or PRP-like eruption secondary to COVID-19 vaccine is exceedingly rare, with only 17 cases previously reported to date in the English literature. In this article, we describe an additional case of COVID-19 vaccination-associated PRP in a 50-year-old woman with a history of metastatic breast carcinoma, who developed a widespread cutaneous eruption characteristic of PRP, including palmoplantar keratoderma, 10 days after her third dose of Moderna COVID-19 vaccine. Punch biopsy specimen showed epidermal hyperplasia with overlying hyperkeratosis, alternating orthokeratosis and parakeratosis and focal follicular plugging, supporting the diagnosis of PRP. The patient improved within weeks of initiating oral acitretin and topical steroids, with resolution achieved after 3 months of continued therapy. To the best of our knowledge, this is the third reported case of Moderna COVID-19 vaccination-associated PRP and collectively the 18th after the administration of all COVID-19 vaccines currently available, including Pfizer–BioNTech, and AstraZeneca.
KW - COVID-19
KW - cutaneous adverse effects
KW - Moderna
KW - pityriasis rubra pilaris
KW - vaccination
UR - http://www.scopus.com/inward/record.url?scp=85148250510&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85148250510&partnerID=8YFLogxK
U2 - 10.1097/DAD.0000000000002369
DO - 10.1097/DAD.0000000000002369
M3 - Article
C2 - 36626570
AN - SCOPUS:85148250510
SN - 0193-1091
VL - 45
SP - 185
EP - 188
JO - American Journal of Dermatopathology
JF - American Journal of Dermatopathology
IS - 3
ER -